The US pharmaceutical giant Pfizer acquires the Californian biotech group Medivation, specialized in anticancer treatments, with a 14 billion dollar operation. The pharmaceutical company confirms the press reports and indicates that the offer, in cash, is $81,50 per share.
Pfizer maintains the prospects for the current year unchanged but already sees from the first year after the completion of the transaction, a growth in value that translates into a contribution of 5 cents to the earnings per share.
By acquiring Medivation, Pfizer can add to its portfolio the prostate cancer drug Xtandi, which has very high potential and has already generated $2 billion in revenues from early sales.
